245 related articles for article (PubMed ID: 30324319)
1. Somatostatin receptor expression in non-classical locations - clinical relevance?
Bhanat E; Koch CA; Parmar R; Garla V; Vijayakumar V
Rev Endocr Metab Disord; 2018 Jun; 19(2):123-132. PubMed ID: 30324319
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
3.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
4. Distribution and functional significance of somatostatin receptors in malignant melanoma.
Lum SS; Fletcher WS; O'Dorisio MS; Nance RW; Pommier RF; Caprara M
World J Surg; 2001 Apr; 25(4):407-12. PubMed ID: 11344389
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
7. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
8. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
10. Peptide imaging with somatostatin analogues: more than cancer probes.
Cascini GL; Cuccurullo V; Tamburrini O; Rotondo A; Mansi L
Curr Radiopharm; 2013 Mar; 6(1):36-40. PubMed ID: 23470033
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging and therapy of somatostatin receptor positive tumors.
Ivanidze J; Roytman M; Sasson A; Skafida M; Fahey TJ; Osborne JR; Dutruel SP
Clin Imaging; 2019; 56():146-154. PubMed ID: 31121520
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Bal CS; Gupta SK; Zaknun JJ
Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
[TBL] [Abstract][Full Text] [Related]
14. The present and future role of (111)In pentetreotide in the PET era.
Rambaldi PF; Cuccurullo V; Briganti V; Mansi L
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):225-35. PubMed ID: 16172568
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
[TBL] [Abstract][Full Text] [Related]
16. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
[TBL] [Abstract][Full Text] [Related]
17. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.
John M; Meyerhof W; Richter D; Waser B; Schaer JC; Scherübl H; Boese-Landgraf J; Neuhaus P; Ziske C; Mölling K; Riecken EO; Reubi JC; Wiedenmann B
Gut; 1996 Jan; 38(1):33-9. PubMed ID: 8566856
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]